Ash-Mix Allergy Shots: Solving the Multi-Species Fraxinus Puzzle
Ash-mix allergy shots (SCIT) solve a regional prescribing puzzle: in Texas, Oklahoma, and the lower Midwest where white ash, green ash, and Arizona ash ranges overlap, a single-species extract misses roughly 30% of the ambient ash pollen burden. Because all Fraxinus species share Fra e 1 (Ole e 1-like, 88% identity with olive), the mix is immunologically redundant — but geographically rational.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Ash Mixis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Ash Mix Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to ash mix — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of ash mix allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of ash mix immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of ash mix extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for ash mix allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing ash mix extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription ash mix immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat ash mix allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Ash Mix?
The biology, taxonomy, and clinical fingerprint of Ash Mix — the foundation of how SCIT targets it.
Multi-species Fraxinus pollen collected during the January–April North American ash season. All species share Fra e 1 — the mix composition is geographic, not immunologically diverse.
- Scientific name
- Fraxinus spp. (americana, pennsylvanica, velutina)
- Family
- OleaceaeOlive family
- Type
- Spring tree pollen mix
- Native to
- Eastern US (F. americana), central and Plains US (F. pennsylvanica), Southwest and California (F. velutina)
- Allergen proteins
- Fra e 1 (major) — Ole e 1-like family, ~20 kDa; shared across all Fraxinus species; 88% identity with Ole e 1 (olive), 91% with Lig v 1 (privet), 82% with Syr v 1 (lilac) — Niederberger 2002Note: WHO/IUIS characterizes Fra e 1 for European ash (F. excelsior); US species express homologous proteins not separately catalogued as of 2025 (allergen.org)
- Particle size
- ~22 μm, tricolporate
- Avoidance difficulty
- Very difficult
How Ash Mix Allergy Presents
Symptoms by body system — useful for distinguishing Ash Mix sensitivity from overlapping allergies and infections.
Respiratory
- Extended nasal congestion and rhinorrhea spanning January through April in transition zones
- Sneezing and itchy nose from sequential exposure to Arizona ash (Jan–Mar), green ash (Mar), and white ash (Mar–Apr)
- Asthma exacerbations in sensitized patients during the prolonged overlapping ash season
- Chronic cough and postnasal drip through the 4-month ash pollen window
Ocular
- Bilateral allergic conjunctivitis across the January–April exposure window
- Periorbital swelling and redness at peak pollen count days
- Persistent eye irritation throughout the extended multi-species ash season
Dermal
- Contact urticaria from handling ash foliage during spring yardwork
- Generalized skin itching during high-pollen days across the ash season
- Eczema flares in atopic patients during the prolonged spring exposure
Systemic
- Extended fatigue from a 4-month sequential pollen exposure in transition zones
- Sleep disruption from nocturnal nasal blockage during peak January–April counts
- Headache from prolonged sinus pressure
- Reduced quality of life across the winter-spring transition
Ash-mix is less about adding more antigens — all Fraxinus species have essentially the same Fra e 1 protein — and more about making sure the extract reflects what's actually in the air where the patient lives. In Oklahoma and central Texas, patients inhale white ash, green ash, and Arizona ash in sequence from January to April. The mix prescription acknowledges that geographic reality.
When & Where Ash Mix Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Combined peak: Arizona ash January–March, white/green ash March–April — continuous January–April exposure in transition zones· ~12–16 weeks in transition zones (TX, OK, lower Midwest) where all three species overlap seasonally
US Exposure Map
3 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Moderate
- IN:
- Moderate
- OH:
- Moderate
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Moderate
- MO:
- Moderate
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- High
- AR:
- Moderate
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- High
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- High
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Ash Mix Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
All Fraxinus species in ash-mix share Fra e 1, the Ole e 1-like major allergen — cross-reactivity within the mix is essentially complete, so the prescription choice is geographic rather than immunologic. Beyond the mix itself, Fra e 1 cross-protects the full Oleaceae family: olive (88% identity), privet (91%), and Russian olive via Ole e 1-like proteins.
Fra e 1 shares 91% identity with Lig v 1 — strongest Oleaceae cross-reactivity (Niederberger 2002)
Is SCIT Right for Your Ash Mix Allergy?
Answer five questions to see if ash-mix SCIT fits your spring allergy profile.
How severe are your January–April spring tree-pollen symptoms in the transition-zone states (TX, OK, lower Midwest)?
The Ash Mix SCIT Protocol
Ash-mix SCIT uses non-standardized extracts from multiple Fraxinus species combined in proportion to regional pollen contribution. Because all ash species share Fra e 1, mix compatibility is straightforward — confirmed per the 2023 AAAAI/ACAAI JTF GRADE guidelines on multi-allergen formulations.
Dose escalation from the most dilute vial through progressively stronger concentrations. Your allergist verifies that the mix components (white ash, green ash, Arizona ash) are compatible in a single vial — all Oleaceae Fraxinus species are compatible. Traditionally each injection was followed by a 30-minute observation period in the clinic; with Curex, eligible patients self-administer the same escalation schedule at home, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand.
Maintenance injections on a schedule individualized by your allergist sustain Fra e 1 tolerance across the full multi-species ash mix. Because all components share Fra e 1, immunologic tolerance builds uniformly across the mix. Cross-protection to olive and privet via Niederberger 2002 mechanism also develops during maintenance.
After completing 3–5 years, your allergist assesses durable tolerance to the full ash-mix exposure. Duration of lasting benefit varies by patient; many experience several years of reduced spring symptoms post-SCIT.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Ash Mix SCIT
Ash-mix SCIT efficacy is inferred from the Oleaceae cross-protection mechanism rather than a specific ash-mix RCT. No US randomized controlled trial for ash-mix exists as of 2025.
- Fra e 1 / Ole e 1 identity (cross-protection basis)88%Niederberger V, et al. Clin Exp Allergy 2002;32:933–941 — ash AIT cross-protects olive and vice versa via shared Ole e 1-like family
- Fra e 1 / Lig v 1 identity (privet cross-protection)91%Niederberger V, et al. Clin Exp Allergy 2002;32:933–941 — 91% identity establishes Oleaceae-wide cross-protection
- Multi-allergen SCIT support (JTF GRADE 2023)70%Greenhawt M, et al. Ann Allergy Asthma Immunol 2023 — JTF GRADE guidelines confirm multi-allergen mixes are appropriate when extract compatibility is verified
No US randomized controlled trial specific to ash-mix SCIT has been published. The scientific rationale is strong: all Fraxinus species share Fra e 1 (>99% identity within genus) and cross-protect the full Oleaceae family via Niederberger 2002. The AAAAI/ACAAI Practice Parameter and 2023 JTF GRADE guidelines support multi-allergen mixes when components are compatible and regionally appropriate — both conditions are met for ash-mix in transition-zone states.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Ash Mix SCIT Side Effects
Ash-mix SCIT carries the standard inhalant immunotherapy side-effect profile. Local reactions during build-up are expected and common; serious systemic reactions are rare under proper protocols.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Expected wheal and flare; resolves within 30–60 minutes during build-up | Rate 30–50% | Mild |
Injection-site itching Localized pruritus managed with cold compress or pre-injection antihistamine | Rate 25–40% | Mild |
Large local reaction Swelling >5 cm lasting >24 hours; requires dose adjustment per JTF 2023 | Rate 5–10% | Moderate |
Delayed local induration Firm nodule for 1–3 days; resolves spontaneously | Rate 3–8% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis flare Sneezing or rhinorrhea within 30 minutes post-injection; self-limiting | Rate 1–3% | Mild |
Mild urticaria Generalized hives without systemic compromise; requires dose reduction | Rate 0.5–1% | Moderate |
Mild asthma exacerbation Bronchospasm during build-up; pre-injection spirometry standard for asthmatic patients | Rate 0.1–0.5% | Moderate |
Anaphylaxis Managed immediately with epinephrine; with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector is confirmed on hand, with onset typically within 30 minutes | Rate <0.1% per injection | Severe |
Ash-mix serum is sterile-compounded to USP <797>, and with Curex the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand. A 30-minute post-injection self-observation captures the vast majority of systemic reactions. No fatalities from SCIT have been reported in the US in the past decade under proper observation protocols (Greenhawt et al., Ann Allergy Asthma Immunol 2023).
SCIT vs Alternatives for Ash Mix
Transition-zone patients with ash-mix sensitization have four options: SCIT with a geographically appropriate ash-mix — now available as a weekly at-home injection with Curex — sublingual drops, avoidance, or daily antihistamines and nasal steroids.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Best for moderate-severe multi-species ash AR; Oleaceae family cross-protection | Emerging evidence; Ole e 1-based drops show immunologic activity in Oleaceae | Impractical across a 4-month January–April window in ash-dense states | Good for mild-moderate; may be inadequate across extended 4-month window |
| 5-yr cost | $3,500–$15,000 over 5 years | Varies by provider; sold as a general sublingual modality, not Curex's product | Low direct cost; high lifestyle burden | $300–$1,200/year for prescriptions |
| Duration | 3–5 years; weekly build-up then maintenance on a schedule individualized by your allergist | 3–5 years daily drops | Permanent lifestyle restriction | Lifelong daily use during season |
| Convenience | At-home weekly self-injection with Curex for ~6 months; the first injection from each new vial or concentration supervised live in the Virtual Shot Room | At-home; no clinic visits needed | HEPA filtration helps indoors; outdoor avoidance impractical | Convenient daily antihistamines and nasal steroids |
| Safety | Excellent; rare systemic reactions with observation | Lower systemic reaction risk than SCIT | No treatment risk; no disease modification | Well-established safety profile |
| Lasting effect | Years of lasting benefit after completing course | Duration of benefit still being studied | No lasting benefit; symptoms return every spring | No lasting benefit; symptoms return when medications stop |
SCITBest
SLIT
Avoidance
Medications
For transition-zone patients facing a 4-month overlapping ash season with moderate-to-severe symptoms, ash-mix SCIT provides geography-matched Oleaceae-wide cross-protection in a single course. Curex now delivers that same SCIT as a weekly at-home injection with pricing confirmed in a current program quote — the serum is sterile-compounded to USP <797>, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, and a prescribed epinephrine auto-injector is confirmed on hand — so you get the disease-modifying Ole e 1-like protection without the weekly clinic trip.
What Ash Mix SCIT Actually Costs
Most major US insurers cover ash SCIT (including multi-species mixes) under standard allergy benefits when prescribed by a board-certified allergist. Multi-allergen formulations may require documentation that the mix components are clinically indicated. Out-of-pocket cost depends on your plan's deductible and co-insurance. Curex at-home IgE testing identifies specific ash mix sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your ash mix allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Ash Mix SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Ash-mix is prescribed when the patient's regional environment includes multiple Fraxinus species releasing pollen in overlapping seasons. In central Texas, Oklahoma, and the lower Midwest, white ash (Fraxinus americana), green ash (F. pennsylvanica), and Arizona ash (F. velutina) ranges overlap, creating a January–April continuous exposure window. The mix ensures that the SCIT extract reflects the actual airborne species mix the patient inhales — not because the species have different allergens (all Fraxinus share Fra e 1), but because the geographic composition of the extract matters for clinical credibility. In the eastern US where only white ash dominates, a single-species extract is typically sufficient.
No — ash-mix and single-species ash SCIT are immunologically equivalent because all Fraxinus species share the same Fra e 1 major allergen. Fra e 1 has essentially identical sequence identity within the Fraxinus genus (>99%) per Niederberger et al. (Clin Exp Allergy 2002). The difference is geographic and practical: a mix reflects the proportional species composition in the patient's local air. This is the same principle as juniper-mix for Cupressaceae — geography-driven, not immunologically additive. Your allergist selects the mix composition based on your region's Fraxinus species distribution data.
Yes — because Fra e 1 shares 88% sequence identity with olive's Ole e 1 and 91% with privet's Lig v 1, ash-mix SCIT provides cross-protection across the entire Oleaceae family per Niederberger et al. (Clin Exp Allergy 2002). This means a transition-zone patient completing an ash-mix course builds simultaneous tolerance against ash (January–April), olive (April–June in California), and privet (May–July in the Southeast). The Oleaceae cross-protection is a major clinical advantage of ash-anchored SCIT.
Most ash-mix patients notice meaningful improvement during their first spring after reaching maintenance dose — typically 6–9 months into treatment. The immunologic mechanism (declining Fra e 1-specific IgE, rising IgG4 blocking antibodies) typically develops over 12–18 months. Because ash-mix patients face a prolonged 4-month exposure window in transition zones, partial improvements during the first treated season are common and the full benefit generally takes two full ash seasons to manifest. Keeping a symptom-medication diary during the January–April window helps your allergist track progress and make dose adjustments.
Yes — antihistamines can be continued throughout ash-mix SCIT. Your allergist may recommend taking an antihistamine on injection days during the early build-up phase to reduce local reactions. Nasal corticosteroid sprays can also be continued. The goal is to progressively reduce your need for rescue medications over the 4-month ash season — many patients find they need far fewer antihistamines by their second or third year on maintenance.
Ash-mix and juniper-mix are both intra-family multi-species formulations, but they address different botanical families and seasons. Ash-mix combines multiple Fraxinus species (all Oleaceae, all sharing Fra e 1, peaking January–April). Juniper-mix combines multiple Juniperus species (all Cupressaceae, all sharing Jun a 1 pectate lyase, peaking December–April). The two families do not cross-react — ash and juniper require separate extracts and separate SCIT courses. In transition zones where both Oleaceae and Cupressaceae are present (central Texas, Oklahoma), a patient may need both ash-mix and juniper-mix in their SCIT prescription.
Most major US insurers cover ash SCIT under standard allergy benefits when prescribed by a board-certified allergist, including multi-species formulations. The insurer typically requires documentation of the clinical indication — confirmed Fraxinus sensitization and regional species exposure pattern — which your allergist can provide. CPT codes 95115/95117 cover injection administration; 95165 covers extract preparation. Pre-authorization may be required. Your allergist's billing team can provide an estimate of your expected out-of-pocket cost before you start.
Yes — ash-mix SCIT is appropriate for children typically from age 5 upward, using age- and weight-adjusted dosing per the AAAAI/ACAAI Practice Parameters. In transition-zone states where ash is a prominent pediatric aeroallergen across January–April, allergists regularly prescribe ash-containing SCIT for school-age children with persistent spring allergy. Starting SCIT in childhood may reduce the risk of developing new Oleaceae sensitivities (to olive or privet) over time. A pediatric allergist can confirm Fra e 1 sensitization and select the regionally appropriate ash-mix composition. Note: the Curex at-home pilot is currently open to patients age 12 and older; pediatric patients require a trained adult caregiver physically present for every injection. Across all ages, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.